PennyPerformers.com: "Penny Stocks that Perform" picks are: ARMH, CTIC, MNRO, RGUS

Pennyperformers.com "Penny Stocks that Perform" picks are: ARM (NASDAQ: ARMH), Cell Therapeutics, Inc. (NASDAQ: CTIC), Monro Muffler Brake, Inc. (NASDAQ: MNRO), REGI U.S., Inc. (OTCBB: RGUS)

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Jul 7, 2009 -- ARM (LSE: ARM); (NASDAQ: ARMH) announced today that MediaTek Inc, a leading fabless semiconductor company for wireless communications and digital multimedia solutions, has licensed the ARM(R) Mali(TM)-400 MP multicore graphics processing unit (GPU) for its system-on-chip (SoC) technology.

A market leader and pioneer in cutting-edge SoC system solutions for wireless communications, high-definition TVs, DVD and Blu-ray products, MediaTek has licensed the Mali-400 MP GPU for its SoC products. Mali-400 MP technology will enable MediaTek to deliver high graphics performance and graphics rendering with low power consumption. Additionally, the Mali-400 MP multicore GPU provides a level of scalability that enables MediaTek to deliver a range of graphics solutions.

"We have chosen to license ARM Mali technology for its scalability and performance credentials," said MediaTek. "It is vital that we are able to achieve flexibility in our product portfolio."

The combination of the ARM processors previously licensed by MediaTek, with the Mali-400 MP GPU demonstrates ARM's unique position in delivering the market's widest range of power efficient, easily configurable CPU and graphics IP. The ARM Connected Community(TM) of more than 600 Partners includes a graphics ecosystem of leading silicon Partners, device manufacturers and content providers in the graphics industry. These partners are working together to bring Mali GPU-enabled mobile phones and consumer devices to market, with the latest in user interfaces, navigation applications, gaming experiences and Web browsing capabilities.

"MediaTek has a strong record of execution and success in the mobile and digital home market place and we are pleased to be working together to deliver the best graphics technology to meet their customers' needs," said Lance Howarth, general manager, ARM Media Processing Division. "The scalability of the Mali hardware architecture will enable its use in a vast range of MediaTek consumer SoC products."

About Mali Graphics Technology

ARM delivers widely adopted graphics IP solutions, with 29 licensees, including 21 licensees of Mali GPUs. The Mali GPU family scales from the Mali-55 GPU to the Mali-400 MP GPU, which addresses all embedded graphics needs with the widest range of supported performance points. This diverse offering enables ARM to lead in conformance to various open standards and confirms the company's unique position as a world-class supplier of a complete range of hardware and software graphics IP, enabling application developers and device manufacturers to create competitive and cutting-edge designs.

About ARM

ARM designs the technology that lies at the heart of advanced digital products, from wireless, networking and consumer entertainment solutions to imaging, automotive, security and storage devices. ARM's comprehensive product offering includes 32-bit RISC microprocessors, graphics processors, video engines, enabling software, cell libraries, embedded memories, high-speed connectivity products, peripherals and development tools. Combined with comprehensive design services, training, support and maintenance, and the company's broad Partner community, they provide a total system solution that offers a fast, reliable path to market for leading electronics companies.

ARM is a registered trademark of ARM Limited. Mali and Connected Community are trademarks of ARM Limited. All other brands or product names are the property of their respective holders. "ARM" is used to represent ARM Holdings plc; its operating company ARM Limited; and the regional subsidiaries ARM Inc.; ARM KK; ARM Korea Limited.; ARM Taiwan Limited; ARM France SAS; ARM Consulting (Shanghai) Co. Ltd.; ARM Belgium N.V.; ARM Germany GmbH; ARM Embedded Technologies Pvt. Ltd.; ARM Norway, AS and ARM Sweden AB.

Jul 7, 2009 -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it had requested and the EMEA has agreed to an oral explanation in support of the OPAXIO Marketing Authorization Application (MAA) in September, 2009 extending the review for the Committee for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009. In April, 2008 the EMEA accepted for review the MAA for OPAXIO for first-line treatment of patients with advanced non-small cell lung cancer who are performance status 2, based on a non-inferior survival and improved side effect profile. The previously scheduled June, 2009 meeting with the EMEA on OPAXIO did not occur due to conflicts in regulatory schedule as CTI focused on completing the pixantrone New Drug Application (NDA) submission in June, 2009.

"We are pleased that the EMEA has agreed to an in person oral explanation in September allowing the Company and its lung cancer experts adequate time to prepare a thorough review for the Co-rapporteurs in support of our MAA for OPAXIO in non-small cell lung cancer," said James A. Bianco, M.D., CEO of Cell Therapeutics. "The fourth quarter is shaping up to be a pivotal period for the Company."

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

Jul 7, 2009 -- Monro Muffler Brake, Inc. (NASDAQ: MNRO), a leading provider of automotive undercar repair and tire services, will release fiscal 2010 first quarter earnings on July 23, 2009. The Company will host a conference call and audio webcast on Thursday, July 23, 2009 at 11:00 a.m. Eastern Time.

The conference call may be accessed by dialing 888-797-2996 and using the required pass code 9131407. A replay will be available approximately one hour after the recording through Thursday, July 30, 2009 and can be accessed by dialing 888-203-1112. The live conference call and replay can also be accessed via audio webcast at the Investor Info section of the Company's website, located at www.monro.com. An archive will be available at this website through July 30, 2009.

Separately, the Company announced that it will participate in the Oppenheimer & Co. 9th Annual Consumer, Gaming, Lodging & Leisure Conference July 15, 2009 in Boston at 2:45 p.m. Eastern Time. The presentation and webcast for the aforementioned conference can be accessed via the Company's website at www.monro.com under the Investor Info link.

About Monro Muffler Brake

Monro Muffler Brake operates a chain of stores providing automotive undercar repair and tire services in the United States, operating under the brand names of Monro Muffler Brake and Service, Mr. Tire, Tread Quarters Discount Tires, and Autotire. The Company currently operates 739 stores in New York, Pennsylvania, Ohio, Connecticut, Massachusetts, West Virginia, Virginia, Maryland, Vermont, New Hampshire, New Jersey, North Carolina, South Carolina, Indiana, Rhode Island, Delaware, Maine, Missouri and Illinois. Monro's stores provide a full range of services for brake systems, steering and suspension systems, tires, exhaust systems and many vehicle maintenance services.

Jul 7, 2009 -- REGI U.S., Inc. (OTCBB: RGUS)(FRANKFURT: RGJ) and Reg Technologies Inc. (TSX VENTURE: RRE)(OTCBB: REGRF) are pleased to announce that a complete set of manufacturing drawings have been completed and released for competitive bid.

The drawing baseline incorporates the following technical features:

- The new improved RadMax(R) Diesel Engine design has incorporated solutions for vane actuation, cooling, and lubrication. All designs have been incrementally reviewed by the REGI U.S., Inc. and the Fortune 1000 company engineers.

- Extensive computer modeling with COSMOS has produced a lower-weight, higher-strength design. The modeling has lead to an implementation that significantly reduces centripetal forces between the vanes and the seals.

With this approved design, the test program will start shortly after receipt of the RadMax(R) parts and assemblies. The tests will initially validate seal performance, vane actuation, pressurization, and lubrication. A series of tests will verify other technology areas, already proven by extensive analysis.

IMPORTANT TASKS ACCOMPLISHED AS FOLLOWS:

- Rotor cooling system design completed

- Seal lubrication design completed

- The stator ramp design completed driven by an Excel spreadsheet model

- The vane actuator assembly completed reducing weight and friction

- The new vane actuator design does not require any return springs

- The Cam ramp design completed driven by an Excel spreadsheet model

- The Cam incorporates a water-cooling system.

Robert Grisar, Vice President of Engineering, comments, "The objective of the new improved diesel engine design is to make significant improvement over all existing engine designs in use today. The RadMax(R) engine reduces weight, number of parts, and complexity, and will use less fuel, and, therefore, reduce hydrocarbons. The COSMOS analysis on the engine has created a low cost, producible design."

SUMMARY

The design incorporates changes recommended to date by the Fortune Company and REGI U.S., Inc. Engineers have analyzed the stress deflections of the vane actuator forces and these are now acceptable for the new diesel engine implementation.

Fabrication of the new diesel engine parts is now underway and a comprehensive testing program will immediately follow. The goal is to license the technology to interested end users for several different applications.

John Robertson, President of REGI U.S., Inc., wishes to congratulate the REGI and Fortune Company's engineering team for their perseverance and hard work that has accomplished the goal of reducing the size, stress and number of parts in the engine design, including incorporating solutions for the engine cooling and lubrication.

About Reg Technologies Inc. and REGI U.S., Inc.

Reg Technologies Inc. and REGI U.S., Inc. are developing an improved axial vane type rotary engine known as the RadMax(R) rotary technology used in the revolutionary design of lightweight and high efficiency engines, compressors and pumps. The RadMax(R) design was mainly developed by Radian Milparts, a large aerospace company, and assigned to REGI U.S., Inc. in December 2005. The RadMax(R) engine has only two unique moving parts, the vanes (up to 12) and the rotor, compared to the 40 moving parts in a simple four-cylinder piston engine. This innovative design makes it possible to produce up to 24 continuous power impulses per one rotation that is vibration-free and extremely quiet.

The RadMax(R) engine also has multi-fuel capabilities allowing it to operate on fuels including gasoline, natural gas, hydrogen, propane and diesel. REGI U.S., Inc. and its parent company, Reg Technologies Inc., have built and tested a RadMax(R) pump application for demonstration purposes and are currently designing and testing the RadMax(R) diesel for a Fortune 1000 Company intended for aviation, automotive, industrial processes and military applications.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

For More Information Regarding Penny Performers, Contact Jason A. Hilton at: Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com

CONTACT: Jason A. Hilton, PennyPerformers.com Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@pennyperformers.com WWW: http://www.PennyPerformers.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: aerospace, architecture, automotive, aviation, belgium, broker, cancer, ceo, clinical, communications, community, computer, conference, connecticut, consulting, consumer, dealer, delaware, dvd, earnings, electronics, email, e-mail, engineering, entertainment, family, france, frankfurt, gasoline, germany, graphics, hardware, illinois, indiana, industrial, investment, investment opinion, korea, leisure, maine, mali, manufacturing, market, marketing, maryland, massachusetts, media, military, missouri, nasdaq, natural gas, networking, new york, new hampshire, new jersey, north carolina, norway, ohio, online, pennsylvania, peripherals, president, prices, products, propane, rhode island, schedule, securities, security, semiconductors, shanghai, software, south carolina, standards, subscription, sweden, taiwan, technology, training, vermont, video, virginia, water, web, west virginia, wireless, women